Literature DB >> 7605334

Neuroprotective therapeutic strategies. Comparison of experimental and clinical results.

M Gerlach1, P Riederer, M B Youdim.   

Abstract

Mesh:

Substances:

Year:  1995        PMID: 7605334     DOI: 10.1016/0006-2952(95)00051-z

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


× No keyword cloud information.
  6 in total

Review 1.  Potential role of cannabinoids in Parkinson's disease.

Authors:  J Sevcík; K Masek
Journal:  Drugs Aging       Date:  2000-06       Impact factor: 3.923

2.  A serum- and antioxidant-free primary culture model of mouse cortical neurons for pharmacological screen and studies of neurotrophic and neuroprotective agents.

Authors:  Xinyu Yu; Lijia An
Journal:  Cell Mol Neurobiol       Date:  2002-04       Impact factor: 5.046

3.  Strategies for the protection of dopaminergic neurons against neurotoxicity.

Authors:  M Gerlach; K L Double; M B Youdim; P Riederer
Journal:  Neurotox Res       Date:  2000       Impact factor: 3.911

4.  Early institution of bromocriptine in Parkinson's disease inhibits the emergence of levodopa-associated motor side effects. Long-term results of the PRADO study.

Authors:  H Przuntek; D Welzel; M Gerlach; E Blümner; W Danielczyk; H J Kaiser; P H Kraus; H Letzel; P Riederer; K Uberla
Journal:  J Neural Transm (Vienna)       Date:  1996       Impact factor: 3.575

Review 5.  Pharmacokinetic optimisation in the treatment of Parkinson's disease.

Authors:  M Contin; R Riva; F Albani; A Baruzzi
Journal:  Clin Pharmacokinet       Date:  1996-06       Impact factor: 6.447

6.  Behavioral and antioxidant activity of a tosylbenz[g]indolamine derivative. A proposed better profile for a potential antipsychotic agent.

Authors:  Chara A Zika; Ioannis Nicolaou; Antonis Gavalas; George V Rekatas; Ekaterini Tani; Vassilis J Demopoulos
Journal:  Ann Gen Hosp Psychiatry       Date:  2004-01-07
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.